ABSTRACT
Nowadays, drug-induced liver toxicity (DILT) is one of the main contributing factors to severe liver disease. In the United States (US) alone, DILT is the cause of more than 50% of instances of acute liver failure. Prescription or over-the-counter drugs, xenobiotics, and herbal and nutritional supplements can cause DILT and could produce anomalies in hepatic function tests. Some drugs induce hepatotoxicity directly, and others induce it indirectly (i. e. through their toxic or reactive metabolites). Currently, the United States Food and Drug Administration (US FDA) has issued black box warnings for about 1279 drugs due to their hepatotoxicity. When we analyzed their mechanism in inducing hepatotoxicity, we found nearly 18 drugs causing hepatotoxicity by their toxic metabolites. In this review, we attempted to highlight the well-known drugs that induce hepatotoxicity indirectly through their toxic metabolites including the enzymes involved in the formation of these metabolites. The Cytochrome P-450 (CYP), Hypoxanthine phosphoribosyltransferase 1, Alcohol oxidase, Uridine diphosphate (UDP)-glucuronosyltransferases, Xanthine dehydrogenase, Purine-nucleoside phosphorylase, Xanthine oxidase, Thiopurine S-methyltransferase, Inosine-5'-monophosphate dehydrogenase, and aldehyde dehydrogenase are involving in the formation of toxic metabolites. The metabolic reactions and enzymes discussed in this review help toxicologists, pharmacologists, and chemists to design and develop hepatotoxicity-free pharmaceutical products containing the inhibitors of these enzymes to reduce hepatotoxicity and improve human health.
Subject(s)
Chemical and Drug Induced Liver Injury , Chemical and Drug Induced Liver Injury/metabolism , Chemical and Drug Induced Liver Injury/etiology , Humans , Animals , Liver/drug effects , Liver/metabolism , Drug-Related Side Effects and Adverse Reactions/metabolismABSTRACT
The COVID-19 pandemic has resulted in a significant number of individuals experiencing the loss of smell and taste, medically known as anosmia and ageusia, respectively. While many patients recover these senses during the post-acute phase of the illness, a subset of individuals continues to suffer from anosmia and ageusia even after recovering from COVID-19. This article aims to explore the psychological state of COVID patients who have not regained their sense of smell and taste post-recovery, highlighting the potential impact on their mental health and overall well-being. To accomplish this, a comprehensive review of existing literature on the topic has been conducted, analyzing studies and reports that shed light on the psychological consequences of unrecovered anosmia and ageusia in COVID patients.
